EP3628319

SALIX PHARMACEUTICALS, INC.
Application Number
EP19207534A
Filing Date
Oct 2, 2009
Status
Granted And Under Opposition
Jan 12, 2024
Grant Date
Feb 14, 2024
External Links
Slate, Register

Biblio Summary

The patent EP3628319B1 was granted on Feb 14, 2024 by Salix Pharmaceuticals, Inc. The patent is currently Granted And Under Opposition.

The table below shows 6 patent oppositions filed on the patent at EPO, listing each opposing company and filing date. Tracking these filings indicates that the applicant is active in this industry, while opposing companies may be signaling their own interest in competing within the same space. These disputes are essential for insights into competitor actions, patent strategy and emerging technological trends.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

ACCORD HEALTHCARE LTDNov 14, 2024ADMISSIBLE
CMS CAMERON MCKENNA NABARRO OLSWANG LLPNov 14, 2024ADMISSIBLE
HOLLATZ, CHRISTIANNov 14, 2024ADMISSIBLE
STADA-ARZNEIMITTEL AKTIENGESELLSCHAFTNov 13, 2024ADMISSIBLE
TEVA PHARMACEUTICAL INDUSTRIES LTD.Nov 12, 2024ADMISSIBLE
HGF LIMITEDNov 4, 2024ADMISSIBLE

The table below shows the patents of Salix Pharmaceuticals, Inc. that have been opposed by other companies.

Patent NumberTitleGrant DateOpposition Count
EP2252148Methods For Treating Bowel DiseasesMar 20, 20193